No anti-aging peptide has a human lifespan trial. The closest thing in the published record is epithalamine, a peptide preparation extracted from cattle pineal glands, given in repeated courses to elderly coronary patients and followed for 12 years in a randomized study. Deaths in the treated group came in 28% lower than in the control group. The compound sold online today as epitalon is a different substance, a synthetic four-amino-acid peptide whose only human record is two small uncontrolled studies from the same research group; it has no published human longevity trial, no dedicated human safety trial, and no FDA approval for anything.
Peptides commonly discussed for anti-aging
Safety: This page is educational content, not medical advice, diagnosis, or treatment, and nothing on it is a dose or a recommendation. Epitalon, MOTS-c and injectable GHK-Cu are sold labeled for research use only, so no agency has verified sterility, identity or purity of what is in the vial, and injecting an unverified product carries infection and contamination risk. Telomerase activation, meaning nudging cells to rebuild telomeres, the protective caps on chromosome ends that shorten with age, is a theoretical cancer concern, so anyone with active or recent cancer should not be experimenting with telomere-targeting compounds. Thymosin alpha-1 modulates immune function and is a specific problem for anyone on immunosuppression after a transplant. There are no peptide options in pregnancy or breastfeeding, and the retinoid this page rates as the stronger wrinkle option is itself avoided in pregnancy, so pregnancy rules out both sides of that comparison. Talk to a clinician who knows your history before starting anything, and treat sudden fever, spreading redness or pain at an injection site as a reason to seek medical care the same day.
Where to buy
Where to get peptides for anti-aging
Save 10% at checkout with code tcwisiiu
Some links are affiliate links — we may earn a fee at no extra cost to you. Most peptides aren't FDA-approved — consult a qualified clinician and check your local laws before purchasing.
No peptide has been tested for whether it makes a human live longer. The closest thing in the published record is a 12-year randomized Ukrainian study of epithalamine, a peptide preparation extracted from cattle pineal glands, given as repeated courses to elderly patients with coronary disease and accelerated cardiovascular aging. After 12 years, deaths in the epithalamine group were 28% lower than in the control group, and cardiovascular deaths were half 1. That study is the strongest human longevity signal anyone in this category has, and it was run on a substance you cannot buy.
What vendors sell as epitalon (also spelled epithalon) is a synthetic four-amino-acid peptide derived from that extract. Its only human record is two small open-label studies from the same research circle, one on retina condition in retinitis pigmentosa and one on melatonin rhythm in elderly subjects 1011. It has no human longevity trial, no dedicated human safety trial, and no FDA approval. The same gap between the thing that was studied and the thing that is on sale runs through most of this category, which is why an honest anti-aging page has to grade the evidence compound by compound.
Are peptides good for anti-aging?
For skin, one class of peptide product is legal, cheap and mildly supported: topical cosmetic peptides, whose best randomized trial was negative on objective measures 3. For the body, the injectable longevity peptides (epitalon, MOTS-c, thymosin alpha-1, elamipretide) sit somewhere between a rare-disease drug and a rodent finding, and not one of them has been tested against an aging endpoint in healthy adults. No peptide has been shown to slow human aging. The threads worth watching are epithalamine's mortality follow-up and elamipretide's approved mitochondrial mechanism, the two with real human data attached.
Anti-aging is also the goal where the word peptide covers products that have nothing to do with each other. A jar of face cream with a copper tripeptide in it, a vial of research-chemical powder shipped from overseas, a scoop of collagen protein and an FDA-approved orphan drug all land under the same search term. They belong on different rungs of the ladder below.
The evidence ladder in one table
| What it is | Best human evidence | What was measured | US regulatory status |
|---|---|---|---|
| Epithalamine (cattle pineal extract) | 12-year and 15-year randomized controlled follow-ups in elderly coronary patients, single collaborating research circle 12 | Deaths, cardiovascular aging, exercise tolerance, melatonin rhythm | Not sold in the US, not FDA-approved |
| Epitalon (synthetic tetrapeptide) | None for longevity; no controlled safety trial. Two small open-label studies 1011 | Retina condition in retinitis pigmentosa; night melatonin in elderly subjects | Not FDA-approved, sold labeled research use only |
| Topical GHK-Cu (copper peptide) | One randomized facial trial, 13 patients, negative on blinded between-group measures 3 | Redness, wrinkles, skin quality, patient satisfaction | Sold as a cosmetic, no FDA efficacy review |
| Thymosin alpha-1 | Randomized double-blind placebo-controlled trial in 90 men aged 65 to 99 6 | Influenza antibody response after vaccination | Approved in a number of countries abroad as thymalfasin, not FDA-approved |
| Elamipretide (SS-31) | Randomized crossover in 12 Barth syndrome patients; neither primary endpoint met, open-label extension positive 5 | 6-minute walk distance, symptom score | Accelerated approval for Barth syndrome only, on a muscle-strength surrogate, pending confirmatory trials 13 |
| MOTS-c | None; discovery and metabolic effects are mouse and cell work 7 | Insulin sensitivity and body weight in mice | Not FDA-approved, sold labeled research use only |
| Training, sleep, blood pressure and lipid control | Randomized trials and large cohorts with death as the endpoint | All-cause mortality | Standard care |
The bottom row is the honest comparator. The boring interventions are the only entries in that table whose evidence base was built on people dying less often, and none of them is a peptide. Anything layered on top is a bet on mechanism.
The extract that was studied and the peptide that is sold
Oleg Korkushko's group at the Institute of Gerontology in Kyiv and Vladimir Khavinson's group in St Petersburg form the single collaborating research circle behind decades of work on pineal peptide preparations. The human work used epithalamine, the extract. In the 15-year randomized comparative follow-up, 39 coronary patients received repeated epithalamine courses on top of standard therapy (6 courses over 3 years) while 40 coronary patients received standard therapy alone; the treated group aged more slowly on cardiovascular measures and died less often 2. The earlier 12-year randomized report from the same program is where the 28% mortality difference comes from 1.
Epitalon, the synthetic tetrapeptide (Ala-Glu-Asp-Gly), was designed from that extract and is what every vendor ships. Beyond the two small open-label studies noted above 1011, its record is animal work and cell work from the same laboratory lineage. Two caveats belong permanently next to any epitalon claim: the human longevity data is for a different substance, and the entire corpus comes from one collaborating research circle without independent replication. That is one strong unreplicated dataset, and it is not a validated result.
| Epithalamine | Epitalon | |
|---|---|---|
| What it is | Peptide preparation extracted from cattle pineal glands | Synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) |
| Human longevity data | 12-year and 15-year randomized controlled follow-ups in elderly coronary patients 12 | None published |
| Human safety trial | Reported within the same follow-ups, same research circle | None dedicated; human exposure limited to two small open-label studies 1011 |
| Independent replication | None | None |
| Can you buy it | No | Yes, labeled research use only |
This analog swap keeps happening in the peptide market, where the compound with the data and the compound in the vial share a name and little else. Our <a href="/peptides-for/sleep">sleep goal page</a> hit the same problem with epitalon's circadian claim.
The load-bearing circadian citation for epitalon is 38 aged rhesus monkeys, not humans.
For compound-level detail on dosing history, cycling, and what the Khavinson corpus does and does not contain, see the <a href="/peptides/epithalon">epithalon peptide page</a>.
Peptides vs retinol for anti-aging
Topical retinoids have the stronger evidence base for wrinkles, and the gap is wide. The comparison below puts the foundational photoaging trial next to the only randomized controlled trial of topical GHK-Cu in the peer-reviewed record; that trial's funding is not clearly disclosed, and a GHK-Cu skincare brand promotes the study in its own marketing.
Topical retinoid vs topical copper peptide, judged by their best trials
Objective evaluation found no significant improvement in wrinkles or overall skin quality. However, patient satisfaction was significantly higher for those who used GHK-Cu skin care products after CO2 laser skin resurfacing.Miller TR et al., Archives of Facial Plastic Surgery, 2006 [[3]]
For wrinkles, a retinoid is the evidence-backed active, and a peptide serum is a comparatively low-risk addition for most users, though it has weak outcome data and no controlled long-term safety data behind it. Our <a href="/peptides-for/skin-aging">skin aging page</a> owns the routine-level detail, including which peptide claims come from cell culture and which come from skin.
The GHK-Cu literature is mechanism-rich and outcome-poor.
Which peptides are best for anti-aging?
GHK-Cu has the most products and the least outcome data
GHK-Cu is a three-amino-acid peptide (glycyl-histidyl-lysine) bound to copper. Plasma GHK falls with age, from roughly 200 ng/mL around age 20 to about 80 ng/mL by 60, and that figure traces back to Loren Pickart's own review literature 12; Pickart founded a copper-peptide company, and we could not find an independent measurement series behind the numbers. Even taken at face value, the decline does not establish that putting GHK-Cu back changes an aging outcome. Cell-culture work shows collagen synthesis, the one randomized facial trial showed no objective benefit over control 3, and injectable GHK-Cu has no human trials at all. Compound-level detail sits on the <a href="/peptides/ghk-cu">GHK-Cu page</a>.
Thymosin alpha-1 has the clearest randomized result in older adults
Thymosin alpha-1 is a 28-amino-acid peptide that pushes T-cell function, the arm of the immune system that fades with age. In a 1989 report, Gravenstein and colleagues randomized 90 men aged 65 to 99 to thymosin alpha-1 or placebo alongside the 1986 trivalent influenza vaccine, dosing 900 micrograms per square metre of body surface subcutaneously twice weekly for eight doses, and reported a greater antibody response in the treated men, most clearly in those aged 77 and older, with no toxicity observed in either group 6. That is a genuine randomized human result on an aging-relevant endpoint, which is more than any other compound here can claim for healthy older adults. Thymosin alpha-1 is approved in a number of countries outside the US as thymalfasin for hepatitis B and C. It is not FDA-approved in the United States, and the only lawful route to it in the US is enrollment in a clinical trial. See the <a href="/peptides/thymosin-alpha-1">thymosin alpha-1 page</a> for the wider trial base.
Elamipretide is the most tested and mostly negative against placebo
Elamipretide, known in the research literature as SS-31, binds cardiolipin in the inner mitochondrial membrane, the lipid that keeps the cell's energy machinery organized. In TAZPOWER, 12 patients with Barth syndrome took 40 mg per day or placebo for 12 weeks each in a randomized crossover design. Neither primary endpoint was met. Ten patients continued into an open-label extension with no placebo group and eight reached 36 weeks, where 6-minute walk distance had improved by 95.9 metres (p = 0.024), with symptom scores also improving 5. FDA granted accelerated approval in September 2025, but not on the walk-distance result: the approval rests on improvement in knee extensor muscle strength as an intermediate clinical endpoint, is indicated to improve muscle strength in patients weighing at least 30 kg, and stays contingent on confirmatory trials 13. Read the full version on the <a href="/peptides/ss-31">SS-31 (elamipretide) page</a> before anyone sells it to you as a proven longevity drug.
The randomized part failed and the uncontrolled part succeeded, which is the exact pattern that makes an open-label result hard to trust.
MOTS-c is a mouse finding with a human market
MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA rather than in the cell nucleus, first reported in 2015 by Changhan Lee and colleagues in Pinchas Cohen's lab at USC 7. In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and blocked diet-induced obesity, acting mainly on skeletal muscle through AMPK activation 7. Every one of those results is in mice. No published human efficacy trial exists for MOTS-c, and it is sold labeled research use only. The <a href="/peptides/mots-c">MOTS-c page</a> tracks the observational human data and why none of it is an efficacy trial.
NAD+ is a coenzyme, not a peptide
NAD+ turns up on nearly every longevity peptide list and it is not a peptide. NAD+ is nicotinamide adenine dinucleotide, a small coenzyme that carries electrons in energy metabolism, with its own separate literature on precursors and infusions. Filing it under peptides makes the peptide evidence look broader than it is; our <a href="/peptides/nad-plus">NAD+ page</a> covers it on its own terms. Tesamorelin is the reverse case: a real FDA-approved peptide drug, approved for HIV-associated lipodystrophy and not for aging, covered on the <a href="/peptides/tesamorelin">tesamorelin page</a>.
What the studies dosed
| Compound | What was given | Route | Duration | Population |
|---|---|---|---|---|
| Epithalamine (extract) | Repeated courses, 6 courses over 3 years 2 | Injection | Followed 12 to 15 years | Elderly coronary patients, 39 treated vs 40 control |
| Epitalon (synthetic) | Short courses in two small open-label studies; dosing not reported in retrievable detail 1011 | Injection | Days to weeks | Retinitis pigmentosa patients; elderly adults |
| Topical GHK-Cu | Commercial GHK-Cu skincare regimen vs the same regimen without it 3 | Topical | 12 weeks | 13 adults after CO2 laser resurfacing |
| Topical tretinoin | Tretinoin cream vs vehicle cream, forearm and face 4 | Topical | 16 weeks | 30 adults with photoaged skin |
| Thymosin alpha-1 | 900 mcg per square metre, twice weekly, 8 doses 6 | Subcutaneous | 4 weeks around vaccination | 90 men aged 65 to 99 |
| Elamipretide | 40 mg per day 5 | Subcutaneous | 12 weeks per arm, then a 36-week extension | 12 patients with Barth syndrome |
| MOTS-c | Mouse dosing only 7 | Intraperitoneal (mice) | Weeks | Mice |
Can a biological age test tell you it is working?
Epigenetic clocks estimate biological age from DNA methylation, the chemical tags that accumulate on your genome in age-related patterns. They are the measure people most want to move on a longevity protocol and the hardest to interpret, because the test itself is noisy.
Epigenetic clocks are widely used aging biomarkers calculated from DNA methylation data, but this data can be surprisingly unreliable. Here we show technical noise produces deviations up to 9 years between replicates for six prominent epigenetic clocks, limiting their utility.Higgins-Chen AT et al., Nature Aging, 2022 [[8]]
That noise means a reported reversal of a few years on a single before-and-after clock reading cannot be separated from the assay bouncing around. If you track a clock, use a provider that reports the principal-component versions (re-engineered clocks that average across thousands of DNA sites so repeat runs agree within about 1.5 years instead of 9), repeat the measurement rather than trusting one draw, and treat the result as an experiment rather than a scoreboard. The cheaper markers move more honestly anyway: hs-CRP for inflammation (our <a href="/peptides-for/inflammation">inflammation page</a> covers what moves it), HbA1c and fasting insulin for metabolism, ApoB for cardiovascular risk, VO2 max for function. Moving a biomarker is still not the same as aging more slowly.
What your genetics tells you here, and what it does not
Aging genetics is real and well studied. Peptide-response genetics in aging is not. Willcox and colleagues found that FOXO3A genotype is strongly associated with human longevity, with the rs2802292 G allele carried more often by Japanese-American men reaching very old age in the Honolulu cohort 9, and the association has since been reported in other populations. No one has run an intervention trial that grouped people by FOXO3, SOD2, TERT or any other variant and measured whether a peptide worked better in one group.
- FOXO3 rs2802292 tells you something about baseline odds of exceptional longevity 9. It has never been tested as a predictor of response to any compound on this page.
- SOD2 Ala16Val (rs4880) shapes how efficiently the mitochondrial antioxidant enzyme is imported into mitochondria. Consumer files report it on different strands, so read it by amino acid rather than by a bare letter. No mitochondrial peptide trial has been stratified by it.
- TERT and telomere-length SNPs (single-letter DNA variants) sit on the pathway epitalon is claimed to act on. The connection between that genotype and any peptide response is a hypothesis with no trial behind it.
- APOE variants are replicated markers for cardiovascular and neurodegenerative aging. They are a reason to manage ApoB tightly, and not a reason to pick a peptide.
A genetic report is useful here as a map of which aging mechanisms your baseline biology emphasizes, which tells you what to measure and which hypothesis to test first. It is not a response prediction, and we will not sell it as one. The framework for reading a raw file that way is in <a href="/learn/which-peptides-dna-decision-framework">which peptides your DNA points to</a>.
Cost, storage, and the unknowns
- Cost is wildly asymmetric across the ladder. Research-chemical vials of epitalon or MOTS-c are among the cheapest things in the peptide market, elamipretide is an approved orphan drug priced like one, and a generic topical retinoid runs a few dollars a month. Price tells you nothing about what is in the container.
- Peptides ship as lyophilized powder, meaning freeze-dried. Powder is stored cold and dry; once mixed with bacteriostatic water it lives in the fridge and degrades over weeks, not months. The mechanics are in <a href="/learn/how-to-reconstitute-peptides">how to reconstitute peptides</a>, and sterile technique in the <a href="/learn/peptide-injection-hygiene-guide">injection hygiene guide</a>.
- Studies in this category ran long. Epithalamine's signal came from 12 and 15 years of follow-up 12, and the elamipretide crossover took 12 weeks per arm before anything was read out 5. Nothing here reported a result at four weeks, so a protocol judged at four weeks is being judged on feelings.
- The largest unknown is purity. Independent purity testing of longevity research chemicals is sparse, and we are not aware of a published dataset worth quoting a number from. A vial labeled 10 mg has no regulatory obligation to contain 10 mg of anything. If you are comparing suppliers anyway, our <a href="/compare">vendor comparison page</a> lists what each one publishes about third-party testing; those links are affiliate links and we earn a commission if you buy through them, which does not change what we publish or how we grade the evidence.
- Long-term human safety is unknown for epitalon, MOTS-c and injectable GHK-Cu. Unknown is a different word from safe.
What circulates in community protocols
| What circulates | Where it came from | The red flag |
|---|---|---|
| Epitalon 5 to 10 mg daily for 10 days, 2 to 3 times a year | The course structure of the Russian extract research, carried over to the synthetic peptide | The human data behind that schedule was generated with a different substance 12 |
| Cycle everything, 12 weeks on and 4 weeks off | Practitioner habit plus the cycled design of the original studies | No head-to-head human comparison of cycled versus continuous dosing has been published for any compound here |
| Stack epitalon, MOTS-c, elamipretide and thymosin alpha-1 together | Longevity forums | Nothing here has been tested as a stack, and four simultaneous starts make attribution impossible if anything changes |
| Track a methylation clock every 6 months | Consumer clock marketing | Technical noise on some clocks reaches 9 years between replicates, larger than the change being chased 8 |
| Buy the cheapest vial that ships fast | Price sensitivity | Research-chemical vials carry no verified identity, purity or sterility |
What a cycle even is, and the schedules people copy, are laid out in our <a href="/learn/peptide-cycling-protocol">peptide cycling protocol guide</a>. If you are new to the category, start with <a href="/learn/peptides-for-beginners">peptides for beginners</a> rather than with a longevity stack.
Link · U.S. Food and Drug AdministrationBulk drug substances nominated for use in compounding under section 503AFDA's live list of which bulk substances pharmacies may and may not compound. This is where the legal status of individual peptides gets decided, and it is the page to check before believing any vendor's claim about legality.fda.govYour genetics point to which aging mechanisms are worth watching first. Upload the raw DNA file you already have from 23andMe, AncestryDNA or MyHeritage and get a report that maps your markers to the mechanisms discussed here, with the evidence tier stated for all 39 peptides. The report describes your baseline biology; it does not predict your response to any compound and is not medical advice.
Get your DNA report- The anti-aging peptide with the best human data is not the one being sold
Epithalamine is a peptide extract from cattle pineal glands and it carries the only long-term human mortality follow-up in this category [[1]][[2]]. Epitalon is a synthetic tetrapeptide built from that extract, it is what vendors ship, and no one has ever run a longevity trial on it in people. The marketing treats them as one product; the published record treats them as two substances.
- Epigenetic clock noise is larger than the reversals people celebrate
Higgins-Chen et al. measured deviations of up to 9 years between repeat runs of the same sample on six widely used epigenetic clocks [[8]]. Any single before-and-after clock reading smaller than that gap cannot separate a real change from measurement noise.
- The topical peptide evidence is thinner than the retinoid evidence, not equal to it
The one randomized facial trial of topical GHK-Cu, run in patients healing from CO2 laser resurfacing, found no objective difference in wrinkles, redness or skin quality against control [[3]]. The foundational tretinoin photoaging trial found improvement on blinded assessment and on skin biopsy [[4]]. For wrinkles, the retinoid has the stronger evidence base.
Frequently asked questions
Are peptides good for anti-aging?
No peptide has been shown to slow human aging. The strongest human longevity data in the category belongs to epithalamine, a cattle pineal extract with 12-year and 15-year randomized controlled follow-ups from a single collaborating research circle (Korkushko's Institute of Gerontology in Kyiv with Khavinson's St Petersburg group), reporting 28% lower mortality in the treated group [[1]][[2]]. That substance is not sold. Of the compounds you can buy, topical GHK-Cu failed its one randomized facial trial on objective measures [[3]], MOTS-c has mouse data only [[7]], and epitalon's only human record is two small open-label studies, neither about longevity [[10]][[11]]. Thymosin alpha-1 has the clearest randomized human result, on flu-vaccine antibody response in men aged 65 to 99 [[6]], and it is not FDA-approved in the United States.
Peptides or retinol for anti-aging?
Retinoids have the stronger evidence for wrinkles. The foundational tretinoin trial was 16 weeks, randomized, double-blind and vehicle-controlled (the control group got the same cream without the active), and found improvement on blinded assessment and on skin biopsy in treated skin only [[4]]. The one randomized trial of topical GHK-Cu, 13 patients assessed at 12 weeks after CO2 laser resurfacing, found no significant difference in wrinkles, redness or skin quality between groups; only patient-reported satisfaction favored the peptide [[3]]. A peptide serum is a low-risk addition rather than a replacement for a retinoid.
Is epitalon the same thing as epithalamine?
No. Epithalamine is a peptide preparation extracted from cattle pineal glands, and it is the substance in the long-term Ukrainian follow-ups that reported lower mortality and slower cardiovascular aging in elderly coronary patients [[1]][[2]]. Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) derived from that extract, and it is what vendors ship. Epitalon's only published human studies are two small open-label reports from the same research circle: a retinitis pigmentosa study [[10]] and a melatonin-rhythm study in elderly subjects [[11]]. Neither was controlled, neither measured longevity, and there is no dedicated human safety trial. A vendor quoting the extract's results for the synthetic peptide is quoting a study of a different substance.
Can a biological age test show whether an anti-aging peptide is working?
Not reliably from one before-and-after reading. Higgins-Chen and colleagues measured deviations of up to 9 years between repeat runs of the same sample on six widely used epigenetic clocks, then built principal-component versions of those clocks (re-engineered to average across thousands of DNA sites) that agreed within about 1.5 years [[8]]. A reported reversal smaller than the assay's own noise cannot be separated from the noise. If you track a clock, use the principal-component versions, repeat the measurement, and pair it with cheaper markers such as hs-CRP, HbA1c, fasting insulin, ApoB and VO2 max.
Sources13
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-359.
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. [Published title reads pituitary gland; the paper's own abstract describes the preparation as pineal and names the drug epithalamin.]
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259.
- Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ. Topical tretinoin improves photoaged skin: a double-blind vehicle-controlled study. JAMA. 1988;259(4):527-532.
- Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome (TAZPOWER). Genet Med. 2021;23(3):471-478.
- Gravenstein S, Duthie EH, Miller BA, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one: a double-blind placebo-controlled clinical study. J Am Geriatr Soc. 1989;37(1):1-8.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
- Higgins-Chen AT, Thrush KL, Wang Y, et al. A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking. Nat Aging. 2022;2(7):644-661.
- Willcox BJ, Donlon TA, He Q, et al. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci USA. 2008;105(37):13987-13992.
- Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-368.
- Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh, et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people [Article in Russian]. Adv Gerontol. 2007;20(1):74-85.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987.
- U.S. Food and Drug Administration. Drugs@FDA record for FORZINITY (elamipretide hydrochloride), NDA 215244; accelerated approval for Barth syndrome, September 2025, on knee extensor muscle strength as an intermediate clinical endpoint.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
This page is educational and is not medical advice. Peptides are not intended to diagnose, treat, cure, or prevent any disease, and most are not FDA-approved. Talk to a qualified healthcare provider before starting anything. Availability and legal status of peptides vary by jurisdiction.
← All condition guides